General
Preferred name
EXISULIND
Synonyms
Sulindac sulfone ()
CP248 ()
Prevatec ()
FGN-1 ()
Sulindac sulphone ()
Sulindac related compound b ()
Aptosyn ()
P&D ID
PD002609
CAS
59973-80-7
59864-04-9
Tags
available
drug
Drug indication
Colorectal cancer
prostate adenocarcinoma
Drug Status
approved
investigational
Max Phase
3.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 63
DESCRIPTION Non-steroidal anti-inflammatory compound (NSAID); metabolite of sulindac (LOPAC library)
DESCRIPTION Exisulind (CP248) induces apoptosis through the activation of protein kinase G (PKG). Exisulind exhibits antineoplastic activity in solid tumour and haematological cancer cell lines and is an inhibitor of tumour growth in rodent models of colon, prostate, bladder, mammary and lung cancer. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
1
Compound Sets
12
ChEMBL Drugs
CHEMBL488025
Drug Repurposing Hub
DrugBank
DB06246
DrugCentral
3219
DrugCentral Approved Drugs
3219
DrugMAP
DMBY56U
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL488025
MedChem Express Bioactive Compound Library
HY-B1787
NPC Screening Collection
ReFrame library
TargetMol Bioactive Compound Library
T24051
External IDs
42
Properties
(calculated by RDKit )
Molecular Weight
372.08
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
2
cLogP
4.03
TPSA
71.44
Fraction CSP3
0.15
Chiral centers
0.0
Largest ring
6.0
QED
0.88
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Apoptosis
PKG
PDE5A
CDK
Drug Metabolite
MTOR
PPAR
MOA
phosphodiesterase inhibitor
Pathway
Cell Cycle/DNA Damage
Metabolic Enzyme/Protease
PI3K/Akt/mTOR
Vitamin D Related/Nuclear Receptor
Tyrosine Kinase/Adaptors
Source data